News

Inflectra is indicated to treat patients with various severe autoimmune diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The FDA

Based on the DSMB’s recommendation, enrollment in the trial will continue as planned. The HOPE-Duchenne trial is evaluating CAP-1002, Capricor’s lead product candidate, in boys with Duchenne muscular

Pursuant to the acquisition, Citius acquired all of the outstanding shares of LMB common stock in exchange for shares of Citius common stock. LMB is a private, late-stage

The compound, SEP-856, is a potential antipsychotic agent with a novel mechanism of action being investigated as a possible treatment for patients with schizophrenia. The preclinical models for

Accelerated review status enables CHMP to grant an opinion two months earlier than the standard 210-day period. In XBiotech’s case, a decision may happen as early as third

Nimbus will get $400m up front and up to $800m if certain development milestones are reached. The Nimbus Apollo program includes lead candidate NDI-010976 and other preclinical ACC

The CHMP also added an informative statement to the broad indication that relative to Opdivo monotherapy, an increase in progression-free survival (PFS) for the combination of Opdivo with

The TERRA study met its primary endpoint of demonstrating improvement in overall survival (OS) in patients with refractory mCRC whose disease had progressed after approved standard therapies. In

The first study in this program completed enrollment at the end of January and the second study has now completed enrollment. The results from the first study are